Treatment of older patients with immune checkpoint inhibitors in routine clinical care as compared to inclusion in pivotal registration trials

Marie Rose B.S. Crombag; John B.A.G. Haanen; Paul Baas; Jos H. Beijnen; Alwin D.R. Huitema

doi:10.1016/j.jgo.2019.06.001

Treatment of older patients with immune checkpoint inhibitors in routine clinical care as compared to inclusion in pivotal registration trials

Marie Rose B.S. Crombag
, John B.A.G. Haanen
, Paul Baas
, Jos H. Beijnen
, Alwin D.R. Huitema

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	529-532
Number of pages	4
Journal	Journal of Geriatric Oncology
Volume	11
Issue number	3
DOIs	https://doi.org/10.1016/j.jgo.2019.06.001
Publication status	Published - Apr 2020
Externally published	Yes

Access to Document

10.1016/j.jgo.2019.06.001

Cite this

@article{455250e7ade343d7aa69855259724090,

title = "Treatment of older patients with immune checkpoint inhibitors in routine clinical care as compared to inclusion in pivotal registration trials",

author = "Crombag, \{Marie Rose B.S.\} and Haanen, \{John B.A.G.\} and Paul Baas and Beijnen, \{Jos H.\} and Huitema, \{Alwin D.R.\}",

note = "Funding Information: Through John B.A.G. Haanen, NKI has received compensation for advisory roles from Amgen, AZ, Bayer, BMS, Celsius Therapeutics, Gadeta, GSK, Immunocore, Ipsen, MSD, Merck Serono, Neon Therapeutics, Novartis, Pfizer, Roche/Genentech, Seattle Genetics; and NKI has received grants from MSD, BMS, Novartis, and Neon Therapeutics. The other authors declare no conflict of interest in connection with this paper. ",

year = "2020",

month = apr,

doi = "10.1016/j.jgo.2019.06.001",

language = "English",

volume = "11",

pages = "529--532",

journal = "Journal of Geriatric Oncology",

issn = "1879-4068",

publisher = "Elsevier Ltd.",

number = "3",

}

TY - JOUR

T1 - Treatment of older patients with immune checkpoint inhibitors in routine clinical care as compared to inclusion in pivotal registration trials

AU - Crombag, Marie Rose B.S.

AU - Haanen, John B.A.G.

AU - Baas, Paul

AU - Beijnen, Jos H.

AU - Huitema, Alwin D.R.

N1 - Funding Information: Through John B.A.G. Haanen, NKI has received compensation for advisory roles from Amgen, AZ, Bayer, BMS, Celsius Therapeutics, Gadeta, GSK, Immunocore, Ipsen, MSD, Merck Serono, Neon Therapeutics, Novartis, Pfizer, Roche/Genentech, Seattle Genetics; and NKI has received grants from MSD, BMS, Novartis, and Neon Therapeutics. The other authors declare no conflict of interest in connection with this paper.

PY - 2020/4

Y1 - 2020/4

UR - https://www.scopus.com/pages/publications/85081959575

U2 - 10.1016/j.jgo.2019.06.001

DO - 10.1016/j.jgo.2019.06.001

M3 - Letter

C2 - 31208830

AN - SCOPUS:85081959575

SN - 1879-4068

VL - 11

SP - 529

EP - 532

JO - Journal of Geriatric Oncology

JF - Journal of Geriatric Oncology

IS - 3

ER -